Teva to Present Data Demonstrating UZEDY™ (risperidon

UZEDY significantly reduced the risk of relapse by up to 80% and prolonged the time to impending relapse by up to 5.0 times while having a similar safety profile to other formulations of... | May 20, 2023

Related Keywords

United States , Michigan , American , John Kane , Richard Jackson , Eric Hughes , National Alliance On Mental Illness , National Pregnancy Registry For Atypical Antipsychotics , Teva Pharmaceuticals , Mental Health Services Administration , Teva Neuroscience Inc , Us National Institutes Of Health , Department Of Psychiatry , Teva Pharmaceutical Industries Ltd , American Psychiatric Association , Teva Pharmaceutical Industries , Risperidone Subcutaneous Extended Release Study , Maintenance Treatment , Executive Vice President , Chief Medical Officer , Assistant Clinical Adjunct Professor , Michigan School , Medicine Department , Barbara Zucker School , Identify Unique Patient Segments Within , Tardive Dyskinesia Population , Tardive Dyskinesia , Geographic Region , Social Determinants , Long Acting Subcutaneous Antipsychotic , Long Term Safety , Tolerability Study , Clinical Dilemmas Surrounding , Long Acting Injectable Antipsychotic Agents , Adverse Reactions , Malignant Syndrome , Motor Impairment , National Pregnancy Registry , Atypical Antipsychotics , Hepatic Impairment , Prescribing Information , Pharmaceutical Industries , Private Securities Litigation Reform Act , Quarterly Report , Annual Report , Current Prescribing , Nova Science , From Phenomenology , Mental Illness , Placebo Controlled Study , Subcutaneous Use , Adolescent Patients With , Adolescent Patients With Schizophrenia , Mental Health Services , Teva Pharmaceutical Industries Limited Stock Exchange , News , Information , Press Release , Zedy , Ignificantly , Educed , The , Risk , F , Relapse , Y , P , O , End , Bprolonged , Dime , Impending , Times , Chile , Caving , Similar , Safety , Profile , Mother , Ormulations Teva Us8816242098 ,